Tandem Diabetes Care Announces First Quarter 2021 Financial Results and Updated Full Year 2021 Sales Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Tandem Diabetes (TNDM) Tops Q1 EPS by 8c, Revenues Beat; Offers FY21 Revenues Guidance Above Consensus
May 5, 2021 4:38 PM EDTTandem Diabetes (NASDAQ: TNDM) reported Q1 EPS of ($0.08), $0.08 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $141 million versus the consensus estimate of $121.96 million.
First Quarter 2021 Highlights
In comparing the first quarter of 2021 to the same period of 2020:
Worldwide pump shipments increased 46 percent to 25,352 pumps from 17,378 pumpsSales increased 44 percent to $141.0 million from $97.9 millionGross margin improved to 52 percent of sales from 51 percentOperating margin... More